RxTrials Institute Drug Pipeline Alert

Novavax has enrolled roughly 230 subjects in its Phase I/IIa study of its pandemic influenza vaccine.

Interim findings last December suggested that the vaccine was well tolerated in 70 healthy adults, according to the company.

Based upon its review of these findings, the data and safety monitoring board recommended that the study continue. Results for the upcoming trial are expected in the third quarter of this year.